mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A...